Breaking News, Collaborations & Alliances

Skyhawk Therapeutics, Merck Expand RNA Alliance

Aims to discover and develop novel small molecules that modulate RNA splicing for autoimmune and metabolic diseases

By: Contract Pharma

Contract Pharma Staff

Skyhawk Therapeutics, Inc. has expanded its strategic collaboration with Merck to discover, develop and commercialize small molecules that modulate RNA splicing. Skyhawk will leverage its SkySTAR platform to develop drug candidates directed to multiple new targets for autoimmune and metabolic diseases. Skyhawk is eligible to receive approximately $600 million per program in an upfront payment and, if Merck exercises its option, potential milestones and royalties on sales of commercialized produc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters